Section Arrow
NTRA.NASDAQ
- Natera
Quotes are at least 15-min delayed:2025/11/21 16:06 EST
After Hours
Last
 230.63
-- (--)
Bid
230.25
Ask
240.63
High 235.13 
Low 230.63 
Volume 10.49K 
Regular Hours (Closed)
Last
 230.49
+4.94 (+2.19%)
Day High 
235.89 
Prev. Close
225.55 
1-M High
229.95 
Volume 
2.49M 
Bid
230.25
Ask
240.63
Day Low
223.6 
Open
225 
1-M Low
182.2 
Market Cap 
31.13B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 209.1 
20-SMA 202.17 
50-SMA 185.03 
52-W High 229.95 
52-W Low 125.38 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.29/-1.06
Enterprise Value
31.23B
Balance Sheet
Book Value Per Share
9.07
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
1.70B
Operating Revenue Per Share
6.75
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EXASExact Sciences Corp100.9+0.23+0.23%-- 
After Hours 100.9 0 0.00%
NEOGNeogen Corp5.725+0.315+5.82%879PE
After Hours 5.54 -- --
GHGuardant Health105.35+5.05+5.03%-- 
After Hours 105.42 -- --
DHRDanaher Corp227.39+5.21+2.34%45.72PE
After Hours 227.39 0 0.00%
OPKOPKO Health1.33+0.03+2.31%-- 
After Hours 1.32 -- --
Industry overview quotes are at least 15 minutes delayed
Business Description
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.